An Act
ENROLLED HOUSE
BILL NO. 2748 By: Miller, Conley, West
(Tammy), Hasenbeck, Stark,
Townley, Roe, Baker,
Provenzano, Munson,
Crosswhite Hader, Hefner,
Schreiber, Ranson, Goodwin,
and Fugate of the House
and
Stanley of the Senate
An Act relating to public health and safety;
prohibiting step therapy requirements for certain
drugs for certain conditions; providing definitions;
authorizing a health benefit plan to allow coverage
for prescription drugs for advanced metastatic cancer
and associated conditions without proving step
therapy; and providing an effective date .
SUBJECT: Public health and safety
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. NEW LAW A new section of law to be codi fied
in the Oklahoma Statutes as Secti on 7320 of Title 63, unless there
is created a duplication in numbering, reads as follows:
For the purpose of prohibiting step the rapy requirements for
certain prescription drugs to treat advanced metastatic cancer an d
associated conditions.
As used in this section:
1. "Associated conditions" means the symptoms or side effects
associated with advanced metastatic cancer or its treatm ent and ENR. H. B. NO. 2748 Page 2
which, in the judgment of the health care practitioner, will further
jeopardize the health of a patient if left untreated; and
2. "Advanced metastatic cancer" means cancer that has spre ad
from the primary or original site of the cancer to nearby tissu es,
lymph nodes, or other areas or parts of the body.
SECTION 2. NEW LAW A new section of law to be co dified
in the Oklahoma Statutes as Section 7321 of Title 63, unless there
is created a duplication in numbering, reads as follows:
A. A health benefit plan that provides coverage for advanced
metastatic cancer and associated conditions may not require, be fore
the health benefit plan provides coverage of a prescriptio n drug
approved by the United States Food and Drug Administration, that the
enrollee:
1. Fails to successfully respond to a differe nt drug; or
2. Proves a history of failure of a different dr ug.
B. This section applies only to a drug, the use of which is:
1. Consistent with best practices for the treatment of advanced
metastatic cancer or an associated condition;
2. Supported by peer-reviewed, evidence-based literature; and
3. Approved by the United States Food and Drug Administration.
SECTION 3. This act shall become effective November 1, 2023.
ENR. H. B. NO. 2748 Page 3
Passed the House of Representatives the 7th day of March, 2023.
Presiding Officer of the House
of Representatives
Passed the Senate the 19th day of April, 2023.
Presiding Officer of the Senate
OFFICE OF THE GOVERNOR
Received by the Office of the Governor this ____________________
day of _________________ __, 20_______, at _______ o'clock _______ M.
By: _________________________________
Approved by the Governor of the State of Oklahoma this _____ ____
day of ___________________, 20_______, at _______ o'clock _______ M.
_________________________________
Governor of the State of Oklahoma
OFFICE OF THE SECRETARY OF STATE
Received by the Office of the Secretary of State this __________
day of ___________________, 20_______, at _______ o'clock _______ M.
By: _________________________________